SCHEMBL4758485

SCHEMBL4758485

COC(=O)c1cc(OCC(=O)O)no1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMPD1 P17405 3/20 0.45
CASP3 P42574 1/20 0.43
CASP6 P55212 1/20 0.43
CASP8 Q14790 1/20 0.43
NR1H2 P55055 1/20 0.40
NR1H3 Q13133 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
HTT P42858 1/20 0.39
ADORA2B P29275 1/20 0.39
PKM P14618 1/20 0.38
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
CHRNA4 P43681 1/20 0.37
LMNA P02545 1/20 0.37
GRIA1 P42261 1/20 0.36
GRIA2 P42262 1/20 0.36
GRIA3 P42263 1/20 0.36
GRIA4 P48058 1/20 0.36
POLB P06746 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7896956 0.84 SMPD1 (0.50) SMPD1CASP3CASP6CASP8NR1H2
SCHEMBL4134852 0.83 HCAR2 (0.47) SMPD1L3MBTL1HTTADORA2BPKM
SCHEMBL7311748 0.83 SMPD1 (0.46) SMPD1CASP3CASP6CASP8NR1H2
SCHEMBL4124767 0.82 SMPD1 (0.44) SMPD1L3MBTL1KDM4EALDH1A1POLB
SCHEMBL31286775 0.81 SMPD1 (0.55) SMPD1NR1H2NR1H3ALDH1A1
SCHEMBL32691257 0.81 L3MBTL1 (0.41) SMPD1CASP3CASP6CASP8NR1H2
SCHEMBL25171017 0.81 SMPD1 (0.55) SMPD1CASP3CASP6CASP8NR1H2
SCHEMBL5888236 0.81 SMPD1 (0.58) SMPD1CASP3CASP6CASP8NR1H2
SCHEMBL4124527 0.81 SMPD1 (0.41) SMPD1L3MBTL1HTTADORA2BPKM
SCHEMBL630644 0.81 SMPD1 (0.61) SMPD1CASP3CASP6CASP8NR1H2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7335655-B2 8-heteroaryl xanthine adenosine A2B receptor antagonists KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) 2008-02-26 US disclosed
US-7205403-B2 8-Heteroaryl xanthine adenosine A2B receptor antagonists KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) 2007-04-17 US disclosed
US-20060142309-A1 8-Heteroaryl xanthine adenosine A2B receptor antagonists KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. 2006-06-29 US disclosed
EP-1469856-A4 8-HETEROARYL XANTHINE ADENOSINE A SB 2B /SB RECEPTOR ANTAGONISTS KING PHARMACEUTICALS RES & DEV (US) 2005-06-22 EP disclosed
EP-1469856-A2 8-HETEROARYL XANTHINE ADENOSINE A SB 2B /SB RECEPTOR ANTAGONISTS King Pharmaceuticals Research and Development Inc. (US) 2004-10-27 EP disclosed
US-20030207879-A1 8-Heteroaryl xanthine adenosine A2B receptor antagonists KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. 2003-11-06 US disclosed
WO-2003063800-A2 8-HETEROARYL XANTHINE ADENOSINE A2B RECEPTOR ANTAGONISTS KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) 2003-08-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030207879-A1 8-Heteroaryl xanthine adenosine A2B receptor antagonists ADORA2B, ADORA2A, ADORA1 SMPD1 706/4885CASP3 3788/4885CASP6 3811/4885
US-20060142309-A1 8-Heteroaryl xanthine adenosine A2B receptor antagonists ADORA2B, ADORA2A, ADORA1 SMPD1 1126/4885CASP3 3780/4885CASP6 3853/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.